CAS 2365172-42-3

DT2216

CAS : 2365172-42-3

DT2216 inhibits various Bcl-XL-dependent leukemias and cancer cells, but is significantly less toxic to platelets.DT2216 is a selective B-cell lymphoma, extremely large (BCL-XL), proteolytic targeting chimera (PROTAC).DT2216 targets bcl-XL to the Von Hipp

Formule : C₇₇H₉₆ClF₃N₁₀O₁₀S₄

Degré de pureté : 99.63% - 99.78%

Couleur et forme : Solid

Masse moléculaire : 1542.36

Ref: TM-T13665

DT2216

CAS : 2365172-42-3

DT2216

Degré de pureté : ≥98%

Masse moléculaire : 1542.36g/mol

Ref: 54-BUP21130

DT2216

CAS : 2365172-42-3

DT2216 is a small-molecule anticancer compound, which is a product of rational drug design originating from advanced chemical synthesis techniques. The primary mode of action of DT2216 involves selectively targeting and disrupting BCL-XL interactions with pro-apoptotic proteins. By specifically degrading BCL-XL, DT2216 enhances the induction of apoptosis in cancer cells, thereby addressing the challenge of resistance associated with conventional therapies.

Formule : C₇₇H₉₆ClF₃N₁₀O₁₀S₄

Degré de pureté : 95%Nmr

Masse moléculaire : 1,542.4 g/mol

Ref: 3D-QUD17242